Sera Prognostics Files 8-K Report
Ticker: SERA · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1534969
Sentiment: neutral
Topics: 8-K, disclosure, SEC filing
TL;DR
Sera Prognostics filed a routine 8-K, no major news.
AI Summary
On January 6, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, with the report being filed as of January 7, 2025. No specific financial transactions or material events are detailed in the provided text, beyond the standard reporting requirements.
Why It Matters
This filing serves as a public record of Sera Prognostics' compliance with SEC reporting requirements, indicating ongoing corporate activity.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for disclosure purposes and does not contain information that suggests immediate risk.
Key Players & Entities
- SERA PROGNOSTICS, INC. (company) — Filer
- 0000950170-25-003021 (other) — Accession Number
- 20250106 (date) — Report Date
- 20250107 (date) — Filing Date
- 8071 (other) — Standard Industrial Classification Code
- DE (other) — State of Incorporation
- 261911522 (other) — IRS Number
- 2749 E. PARLEYS WAY (other) — Street Address
- SALT LAKE CITY (other) — City
- UT (other) — State
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to serve as a Regulation FD Disclosure, indicating that the company is making public information available.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 06, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 2749 East Parleys Way, Suite 200, Salt Lake City, Utah, 84109.
What is Sera Prognostics, Inc.'s Standard Industrial Classification (SIC) code?
Sera Prognostics, Inc.'s Standard Industrial Classification code is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
When was Sera Prognostics, Inc. incorporated?
Sera Prognostics, Inc. was incorporated in Delaware.
Filing Stats: 538 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-07 17:21:26
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share SERA The Nasdaq
Filing Documents
- sera-20250106.htm (8-K) — 38KB
- 0000950170-25-003021.txt ( ) — 153KB
- sera-20250106.xsd (EX-101.SCH) — 25KB
- sera-20250106_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract (available at onlinelibrary.wiley.com/doi/epdf/10.1002/pmf2.12035) reporting topline results for the P rematurity R isk Assessment Combined With Clinical I nterventions for Improving Neonatal outco ME s ("PRIME") study. PRIME study results are scheduled to be presented in greater detail at the SMFM 2025 Pregnancy Meeting TM on January 31, 2025 (smfm2025.eventscribe.net/), and the Company will host a conference call and live audio webcast on February 6, 2025, at 12 p.m. ET to further discuss these results. Details of this conference call will be provided closer to the date. The information contained in Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or into any filing or other document pursuant to the Exchange Act, except to the extent required by applicable law or regulation.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERA PROGNOSTICS, INC. Date: January 7, 2025 By: /s/ Austin Aerts Austin Aerts Chief Financial Officer